Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Pancreatic Neoplasms 4Sarcoma 2Neoplasm Metastasis 2Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Melanoma 1Glioma 1Glioblastoma 1

Interventions

antineoplaston AS 2-1 3antineoplaston A10 3dactolisib 2Temozolomide 2Irinotecan 2Everolimus 2Bevacizumab 2surufatinib 1spartalizumab 1poly ICLC 1plerixafor 1pasireotide 1fosbretabulin 1cixutumumab 1adavosertib 1Vaccines 1TH 302 1Sunitinib 1Radiotherapy, Image-Guided 1Radiotherapy 1Radiation 1PM 00104 1Lapatinib 1Immunologic Techniques 1Immunoglobulin G 1Genistein 1Fentanyl 1Donepezil 1Disulfides 1Decitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neuroectodermal Tumors, Primitive × TH 302 × Clear all
NCT02402062 2020-07-27

A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
17 enrolled 55 charts
EndocrineGastrointestinalNET

Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡